12:00 AM
 | 
Dec 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

IW001: Preliminary Phase I data

Preliminary data from an open-label, U.S. Phase I trial in 30 patients with IPF showed that once-daily 0.1, 0.5 and 1 mg doses of IW001 for 24 weeks were well tolerated. There were no changes in lung...

Read the full 165 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >